SAN DIEGO--(BUSINESS WIRE)--Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it will present data for BYDUREON™ (exenatide extended-release for injectable suspension), the first and only once-weekly diabetes treatment, as well as first-in-class diabetes drugs BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate) injection at the 72nd Scientific Sessions of the American Diabetes Association (ADA), June 8-12, 2012, in Philadelphia. The Company will also host an investor presentation and webcast on Sunday, June 10 at 7:30 p.m. ET/4:30 p.m. PT.
